Landfar Bio-medicine Co., Ltd (SHE:000504)
China flag China · Delayed Price · Currency is CNY
8.18
-0.08 (-0.97%)
Nov 6, 2026, 10:25 AM CST

Landfar Bio-medicine Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Net Income
21.3528.83-19.85-28.17-12.46-19.13
Depreciation & Amortization
7.337.345.716.346.216.87
Other Amortization
24.0324.0112.189.159.17.26
Loss (Gain) From Sale of Assets
-0-0-0.16-11.9-0.08-0.03
Asset Writedown & Restructuring Costs
2.442.440.476.920.92.53
Loss (Gain) From Sale of Investments
-7.71-7.71-3.68-0.950.060.31
Provision & Write-off of Bad Debts
12.6712.6712.326.0823.7917.11
Other Operating Activities
-12.57-6.467.47-0.13-2.390.38
Change in Accounts Receivable
-173.67-173.67-37.389.84135.2147.24
Change in Inventory
2.582.58-25.41-6.184.824.29
Change in Accounts Payable
-4.86-4.8654.0425.96140.89
Operating Cash Flow
-129.33-115.744.7936.28166.38107.1
Operating Cash Flow Growth
---86.79%-78.20%55.35%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Capital Expenditures
-12.02-5.12-18.26-5.92-16.94-31.96
Sale of Property, Plant & Equipment
0.230.02017.720.330.07
Cash Acquisitions
-2.44-61.232.53---
Divestitures
-10.86-10.86----
Investment in Securities
100100-98.190.950.490
Other Investing Activities
7.584.085.59--1.74
Investing Cash Flow
82.4926.89-108.3312.75-16.12-30.15

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Short-Term Debt Issued
----75.1455.86
Long-Term Debt Issued
-269.011828--
Total Debt Issued
279.01269.01182875.1455.86
Short-Term Debt Repaid
---159.79-3.77-145-41.96
Long-Term Debt Repaid
--38.05-39.54-66.97-3.17-3.24
Lease Payments
-4.54-4.54-3.54-3.97-3.17-3.24
Total Debt Repaid
-53.06-38.05-199.33-70.74-148.17-45.2
Net Debt Issued (Repaid)
225.95230.96-181.33-42.74-73.0310.66
Issuance of Common Stock
---273.7--
Common Dividends Paid
-3.18-2.37-0.91-3.21-2.4-2.12
Other Financing Activities
-27.4-0.31-0.67-1.12-9.720.47
Financing Cash Flow
194.12228.28-182.91226.63-85.159.02

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Foreign Exchange Rate Adjustments
-0-00000
Net Cash Flow
147.28139.43-286.45275.6665.1185.97

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Free Cash Flow
-141.36-120.85-13.4730.36149.4475.14
Free Cash Flow Growth
----79.68%98.89%-
Free Cash Flow Margin
-18.88%-29.06%-10.02%22.19%74.59%47.97%
Free Cash Flow Per Share
-0.44-0.38-0.040.100.480.24
Levered Free Cash Flow
-61.56-210.28-6.1644.79148.9694.32
Unlevered Free Cash Flow
-60.35-208.66-5.2451.71157.03104.3
Free Cash Flow After Leases
-145.9-125.39-17.0126.39146.2671.9

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash Interest Paid
-----0.13
Cash Income Tax Paid
44.7620.4810.7118.259.2416.06
Change in Working Capital
-176.86-176.86-9.6528.94141.2591.79